Corvus Pharmaceuticals, Inc. (CRVS) is a publicly traded Healthcare sector company. As of July 5, 2026, CRVS trades at $15.23 with a market cap of $1.28B and a P/E ratio of -80.16. CRVS moved +3.32% today. Year to date, CRVS is +103.34%; over the trailing twelve months it is +282.66%. Its 52-week range spans $2.54 to $26.95. Analyst consensus is strong buy with an average price target of $31.60. Rallies surfaces CRVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Corvus Invests $5M in Angel Pharma’s $13.5M Round for Soquelitinib Trials in China: Corvus Pharmaceuticals invested $5 million in a $13.5 million financing round for collaboration partner Angel Pharmaceuticals to advance Phase 1b/2 atopic dermatitis and upcoming Phase 2 asthma trials of soquelitinib in China. Angel Pharma plans initial atopic dermatitis cohort results in late 2026 and Phase 2 asthma initiation in early 2027.
| Metric | Value |
|---|---|
| Price | $15.23 |
| Market Cap | $1.28B |
| P/E Ratio | -80.16 |
| EPS | $-0.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.95 |
| 52-Week Low | $2.54 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.28M |
| Gross Margin | 0.00% |
5 analysts cover CRVS: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $31.60.